Literature DB >> 33375133

A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer.

Klara Hammarström1, Israa Imam1, Artur Mezheyeuski1, Joakim Ekström1, Tobias Sjöblom1, Bengt Glimelius1.   

Abstract

Radiotherapy (RT) or chemoradiotherapy (CRT) are frequently used in rectal cancer, sometimes resulting in complete tumor remission (CR). The predictive capacity of all clinical factors, laboratory values and magnetic resonance imaging parameters performed in routine staging was evaluated to understand what determines an excellent response to RT/CRT. A population-based cohort of 383 patients treated with short-course RT (5 × 5 Gy in one week, scRT), CRT, or scRT with chemotherapy (scRT+CT) and having either had a delay to surgery or been entered into a watch-and-wait program were included. Complete staging according to guidelines was performed and associations between investigated variables and CR rates were analyzed in univariate and multivariate analyses. In total, 17% achieved pathological or clinical CR, more often after scRT+CT and CRT than after scRT (27%, 18% and 8%, respectively, p < 0.001). Factors independently associated with CR included clinical tumor stage, small tumor size (<3 cm), tumor level, and low CEA-value (<3.8 μg/L). Size or stage of the rectal tumor were associated with excellent response in all therapy groups, with small or early stage tumors being significantly more likely to reach CR (p = 0.01 (scRT), p = 0.01 (CRT) and p = 0.02 (scRT+CT). Elevated level of carcinoembryonic antigen (CEA) halved the chance of response. Extramural vascular invasion (EMVI) and mucinous character may indicate less response to RT alone.

Entities:  

Keywords:  Rectal cancer; chemoradiotherapy; comprehensive; population-based; radiotherapy; response prediction

Year:  2020        PMID: 33375133     DOI: 10.3390/cancers13010016

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy.

Authors:  Su-Ping Guo; Chen Chen; Zhi-Fan Zeng; Qiao-Xuan Wang; Wu Jiang; Yuan-Hong Gao; Hui Chang
Journal:  Cancer Manag Res       Date:  2021-03-18       Impact factor: 3.989

2.  Mucinous rectal cancers: clinical features and prognosis in a population-based cohort.

Authors:  Malin Enblad; Klara Hammarström; Joakim Folkesson; Israa Imam; Milan Golubovik; Bengt Glimelius
Journal:  BJS Open       Date:  2022-03-08

Review 3.  Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.

Authors:  Moying Li; Qiyun Xiao; Nachiyappan Venkatachalam; Ralf-Dieter Hofheinz; Marlon R Veldwijk; Carsten Herskind; Matthias P Ebert; Tianzuo Zhan
Journal:  Ther Adv Med Oncol       Date:  2022-02-21       Impact factor: 8.168

4.  H3K27me3 Immunohistochemical Loss Predicts Lower Response to Neo-Adjuvant Chemo-Radiotherapy in Rectal Carcinoma.

Authors:  Serena Ammendola; Nicolò Caldonazzi; Paola Chiara Rizzo; Giulia Turri; Corrado Pedrazzani; Valeria Barresi
Journal:  Biomedicines       Date:  2022-08-21

5.  Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer.

Authors:  Nir Horesh; Michael R Freund; Zoe Garoufalia; Rachel Gefen; Arun Nagarajan; Eva Suarez; Sameh Hany Emile; Steven D Wexner
Journal:  J Gastrointest Surg       Date:  2022-10-12       Impact factor: 3.267

6.  Associations between clinical characteristics and tumor response to neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  Xiaolin Pang; Yuanhong Gao; Hanchen Yi; Hailing Liu; Shuai Liu; Jian Zheng
Journal:  Cancer Med       Date:  2021-06-15       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.